



THE
BLADDER CANCER
COMPANY

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("**Photocure**" or the "**Company**") published on 1 June 2022 regarding initiation of a share buyback program.

The Company has completed its share buyback program. The Company has acquired a total of 36,000 own shares at a price per share of NOK 102.072. A report of all the transactions relating to the buy-back programme, in a detailed form and in an aggregated form is attached.

The shares acquired is used for the Company's incentive scheme and sold to employees.

After the acquisition and sale to employees, Photocure owns 14,641 own shares in the Company.

For further information, please contact:

Photocure

CFO Erik Dahl

Tel: +47 450 55 000

Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052, and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.